Benefits and risks of ponatinib versus bosutinib following treatment failure of two prior tyrosine kinase inhibitors in patients with chronic phase chronic myeloid leukemia: a matching-adjusted indirect comparison.

CONCLUSIONS: Based on these surrogate measures of patient benefit-risk, ponatinib appears to provide a net overall benefit vs. bosutinib in 3L CP-CML. PMID: 30086654 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - Category: Research Tags: Curr Med Res Opin Source Type: research